Rimegepant
Calcitonin Gene-Related Peptide (Cgrp) Antagonists
Sold as VYDURA · NURTEC ODT
- Drug class
- Calcitonin Gene-Related Peptide (Cgrp) Antagonists
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 7
Overview
Rimegepant is an active pharmaceutical ingredient in the Calcitonin Gene-Related Peptide (Cgrp) Antagonists group (N02CD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 5 | April 24, 2026 |
| EU European Union | EMA | 1 | February 26, 2026 |
| CA Canada | Health Canada | 1 | May 13, 2026 |
GBUnited Kingdom· MHRA
5 products
Uses
VYDURA is indicated for the • Acute treatment of migraine with or without aura in adults; • Preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month.
How to take
EUEuropean Union· EMA
1 product
Uses
VYDURA is indicated for the Acute treatment of migraine with or without aura in adults; Preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month.
How to take
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Rimegepant. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB000571717 · revised April 24, 2026
- [2]European Medicines Agency · EMEA/H/C/005725 · revised February 26, 2026
- [3]Health Canada (DPD) · 02543605 · revised May 13, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.